Bioventus Inc

Stage 2’s advancing regime remains intact with an active Lockout Rally driving forced participation. Despite extreme overbought readings, price holding above rising EMAs on pullbacks confirms support, justifying immediate entry to capture the next leg of the breakout.

• ↑Q1 2026 revenue reached $132M, up 7% YoY
• ↑Adjusted EBITDA rose 24% to $24M, margin expanded to 18%
• ↓Profitability score remains weak with high leverage at 1.05x